<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00792558</url>
  </required_header>
  <id_info>
    <org_study_id>CA195-001</org_study_id>
    <nct_id>NCT00792558</nct_id>
  </id_info>
  <brief_title>Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers</brief_title>
  <official_title>A Phase I Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find the maximum tolerated dose of BMS-817378 in subjects
      with advanced cancers
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">November 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the MTD of BMS-817378 when administered orally on a daily schedule in subjects with advanced cancers</measure>
    <time_frame>Within the first 21 days after first dose of BMS-817378</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess safety and tolerability of multiple doses of BMS-817378 administered orally on a once daily schedule in subjects with advanced or metastatic solid tumors</measure>
    <time_frame>All time points while subject is on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the safety and tolerability of co-administration of a CYP substrate cocktail and BMS-817378 given at or below the MTD (dose expansion cohort)</measure>
    <time_frame>Day 22 +/-2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetics of BMS-817378 and its active moiety, BMS-794833</measure>
    <time_frame>Days 1 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effects of BMS-817378 and BMS-794833 on blood pressure, heart rate, ECG intervals, and left ventricular ejection fraction</measure>
    <time_frame>All time points while subject is on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe preliminary evidence for anti-tumor activity of BMS-817378</measure>
    <time_frame>Every 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-817378</intervention_name>
    <description>Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of advanced non-hematologic malignancy. Dose expansion cohort
             restricted to subjects with advanced or metastatic gastroesophageal cancer, squamous
             cell cancers of the head and neck, and castration resistant prostate cancer

          -  ECOG status 0-1

        Exclusion Criteria:

          -  WOCBP unwilling/unable to use acceptable contraception methods, and women pregnant or
             breast feeding

          -  Symptomatic brain metastasis

          -  Uncontrolled or significant cardiovascular disease

          -  History of thromboembolic events or bleeding diathesis in past 6 months

          -  Conditions requiring prophylactic anticoagulation or chronic anti-platelet therapy

          -  Serious non-healing wounds, ulcers or bone fractures in past 3 months

          -  Hemorrhage or bleeding event &gt;= CTCAE grade 3 in past 4 weeks

          -  Proteinuria &gt;= 2+ on dipstick or &gt;= 1gm/24 hours

          -  Concurrent chemotherapy, hormonal therapy, immunotherapy, radiation therapy or therapy
             with any other investigational product

          -  Concurrent herbal, alternative, food supplements, or strong CYP 3A4 inhibitors or
             inducers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2008</study_first_submitted>
  <study_first_submitted_qc>November 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2008</study_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2015</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

